Alnylam Pharmaceuticals news

Strong analyst consensus (18 of 21 buy/strong buy ratings), attractive valuation metrics (19.7x forward earnings, 0.32 PEG ratio), favorable competitive dynamics with rival drug failure, extended patent protection for competing therapy, and promising pipeline. Consensus 12-month price target suggests 44% upside potential.

Listed as a leading company in the expanding oligonucleotide therapeutics market with strong growth projections (23.4% CAGR). The company is positioned to benefit from increasing regulatory approvals, expanding applications, and rising investment in RNA platforms.

Company significantly reduced full-year 2026 TTR product sales guidance by approximately $200 million, resulting in a 28.35% intraday stock price drop. Additionally, the company is now subject to a federal securities investigation for potential violations, indicating serious concerns about prior disclosures and business practices.

The company significantly lowered its full-year 2026 TTR product sales guidance by $200 million due to slower market growth than anticipated. This triggered a substantial 28.35% stock price decline and prompted a securities fraud investigation, indicating serious concerns about the company's market performance and investor confidence.

Company lowered full-year 2026 TTR product sales guidance by $200 million, citing slower-than-expected market growth after initial pent-up demand was satisfied. Stock experienced a significant 28% decline following the announcement, and the company is now subject to a securities fraud investigation.

While the collaboration represents a strategic move aligned with Alnylam's 2030 roadmap for expanding operations, the stock price was down 1.25% at publication, suggesting the market did not react positively to the deal announcement.

Alnylam is mentioned only as a previous employer of the appointed advisor. The mention is factual and does not contain information that would directly impact Alnylam's business or valuation.

Comparable biotech peer with strong revenue growth (+66.9% YoY) and improved EPS ($1.84 vs. $0.32 YoY), but expected to decline -24.5% next quarter. Zacks Rank #3 (Hold) with VGM Score of C indicates neutral outlook similar to TGTX.

Entered at $110 in 2020, reached $491 in October 2025 (346% gain). Fund recognized RNAi platform potential before mainstream market understanding of its commercial applications.

Commercial expansion and late-stage siRNA programs are increasing manufacturing requirements, benefiting from the fastest-growing oligonucleotide category.

FDA approval of AMVUTTRA (vutrisiran) as first RNAi therapy for ATTR-CM with demonstrated cardiovascular benefits; strong market position with approved therapies Onpattro and Amvuttra driving significant revenue growth

Strong Q1 revenue growth (121% YoY), transition to profitability (EPS $1.51 vs loss of $0.14 YoY), robust 2026 guidance (71% growth), expanding pipeline into larger markets, unique RNAi technology moat, and 21 of 29 analysts rating as buy/strong buy with 45% upside potential.

Listed as a market leader in the expanding protein synthesis research market, benefiting from CGT investment momentum and strong pipeline activity.

Established leader with proven RNAi platform, Zilebesiran in Phase III trials, and strong commercial success creating competitive advantages.

Mentioned as competitor with Myqorzo for HCM treatment. Like Bristol Myers Squibb, faces potential competition from Edgewise's safer mechanism, but no specific negative or positive developments mentioned in the article.

Amvuttra is mentioned as a competitive next-generation product gaining market share, but no specific positive or negative catalysts are highlighted in the article.